JointHealth™ express June 5, 2019
Good news for British Columbians living with psoriatic arthritis
BC PharmaCare has recently added ixekizumab (Taltz®) to its provincial formulary for the treatment of psoriatic arthritis.
Ixekizumab is approved by Health Canada for the treatment of psoriatic arthritis and will be reimbursed according to criteria detailed in HLTH 5360 (Initial/Switch) or HLTH 5361 (renewal), and when prescribed by a rheumatologist. BCPharmaCare covers a maximum 28-day supply of ixekizumab per fill. Click here to read the limited coverage drugs listing.
Ixekizumab is an inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the inflammation associated with psoriasis, psoriatic arthritis, and some other inflammatory conditions. Ixekizumab has also been authorized for use in patients with moderate to severe plaque psoriasis.
Good news for British Columbians living with psoriatic arthritis
BC PharmaCare has recently added ixekizumab (Taltz®) to its provincial formulary for the treatment of psoriatic arthritis.
Ixekizumab is approved by Health Canada for the treatment of psoriatic arthritis and will be reimbursed according to criteria detailed in HLTH 5360 (Initial/Switch) or HLTH 5361 (renewal), and when prescribed by a rheumatologist. BCPharmaCare covers a maximum 28-day supply of ixekizumab per fill. Click here to read the limited coverage drugs listing.
Ixekizumab is an inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the inflammation associated with psoriasis, psoriatic arthritis, and some other inflammatory conditions. Ixekizumab has also been authorized for use in patients with moderate to severe plaque psoriasis.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.